Yes you are right this is for the Phase 2 trial that reported back in 2018 (from memory). The same problem exists with this trial's results in that they also missed the primary endpoints so that statistical analysis on the secondary endpoints can't be performed [1]. I am not sure what statistically valid data MSB can give the FDA to work with that isn't post hoc data mining - I guess the positive is the trial size will be relatively small if they are asked to repeat this trial.
1. https://pubmed.ncbi.nlm.nih.gov/30912838/
Yes you are right this is for the Phase 2 trial that reported...
- There are more pages in this discussion • 420 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.030(2.73%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.11 | $1.21 | $1.05 | $28.73M | 25.63M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 14264 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 24626 | 3 |
View Market Depth
| Last trade - 16.10pm 02/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.08 |
Change
-0.030 ( 2.52 %) |
||||
| Open | High | Low | Volume | ||
| $1.10 | $1.21 | $1.05 | 5190842 | ||
| Last updated 15.59pm 02/05/2024 ? | |||||
| MSB (ASX) Chart |